Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad have developed a promising new approach to combat fungal infections. On November 17–18, 2026, the research team led by Dr. Sriram Varahan focused on Candida albicans, a common fungus that can cause serious infections when it spreads through the bloodstream or internal organs.
Understanding Candida albicans and Its Threat
Candida albicans is a fungus that normally exists harmlessly in the human body but can become dangerous under certain conditions. It is known for its ability to switch between different shapes, a process called morphogenesis. This shape-shifting allows the fungus to invade tissues and form biofilms, which are protective layers that make infections harder to treat. When Candida enters the bloodstream, it can lead to systemic infections that are difficult to manage and potentially life-threatening.
Key Discoveries in Blocking Fungal Invasion
Instead of trying to kill the fungus directly, the CCMB team aimed to stop Candida albicans from changing into its invasive filament-like form. They identified two chemical compounds that interfere with glycolysis, the fungus’s sugar metabolism pathway, which is crucial for its shape transformation. Specifically, they found that pyruvate kinase, an enzyme involved in the final step of glycolysis, plays a central role in regulating this morphogenesis.
- The compounds prevent Candida from forming biofilms, which are linked to drug resistance.
- They enhance the effectiveness of existing antifungal drugs like fluconazole and amphotericin B.
- In mouse models of systemic Candida infection, treatment with one of the compounds significantly improved survival rates.
The research was a collaborative effort between CSIR-CCMB and the BRIC-Translational Health Science and Technology Institute (THSTI) and was published in the journal ACS Infectious Diseases. Dr. Varahan emphasized that further studies are needed to evaluate the safety and potential for clinical use of these compounds.
Why This Approach Could Change Fungal Infection Treatment
Traditional antifungal treatments often focus on killing the fungus, but this can lead to resistance and side effects. By targeting the fungus’s ability to change shape and invade tissues, this new strategy offers a way to disarm the pathogen without necessarily killing it outright. This could reduce the pressure on fungi to develop drug resistance and improve the success of existing medications.
Moreover, preventing biofilm formation addresses one of the major challenges in treating fungal infections, as biofilms protect fungal cells from drugs and the immune system. The improvement in survival seen in animal models suggests this approach could lead to more effective therapies for patients with systemic Candida infections, which currently have high mortality rates.
Frequently Asked Questions
Q: What is Candida albicans?
A: Candida albicans is a type of fungus that normally lives harmlessly on the skin and inside the body but can cause infections if it grows uncontrollably or enters the bloodstream.
Q: How does Candida change shape and why is it important?
A: Candida can switch from a round yeast form to filament-like structures through morphogenesis. This shape change helps it invade tissues and form protective biofilms, making infections more severe and harder to treat.
Q: What role does pyruvate kinase play in fungal infections?
A: Pyruvate kinase is an enzyme involved in the fungus’s sugar metabolism. It regulates the shape change process in Candida albicans, making it a key target for blocking fungal invasion and infection.

